Objective: To compare the efficacy and speed of achieving remission/response in treatment-resistant depression (TRD) patients treated with subanesthetic intravenous (IV) ketamine and intranasal (IN) esketamine approved by the US Food…
Read More
Breaking developments in psychiatric research and updates from Psychopharmacology Bulletin.
In a phase 2 study, pimavanserin showed promise as a treatment for major depressive disorder (MDD) when used in combination with other antidepressants. Two phase 3 studies were then conducted…
Read More
The US Food and Drug Administration (FDA) has approved the anti-amyloid beta protofibril antibody lecanemab (Leqembi, Eisai) for the treatment of early Alzheimer's disease (AD). The agency approved the treatment…
Read More
In a study published in PLOS Medicine that uses data spanning 25 years, the authors observed short sleep duration to be associated with risk of chronic disease and subsequent multimorbidity…
Read More
An enzyme that efficiently degrades and metabolizes cocaine has been given a ‘cooperative agreement grant’ from the National Institute on Drug Abuse (NIDA) part of the National Institutes of Health.…
Read More
It is known that psychedelics activate serotonin 2A receptors, which eventually leads to states like increased empathy and out-of-body experiences. One of the key questions remaining n psychedelic medicine is…
Read More
Suicidal behaviors were higher during the school year (average of 6,761/month) compared to school break (average of 4,512/month). Prevalence of suicidal behaviors was highest in October for both hospitalization and…
Read More
Two drugs have emerged as the optimal medications for treating insomnia based on the "best-available evidence," but there are caveats. In a comprehensive comparative-effectiveness analysis, lemborexant and eszopiclone showed the best efficacy, acceptability, and…
Read More
Whereas symptoms of depression are known to intensify in patients who have recently experienced an incident stroke, it might also be true in such cases that the depression actually starts to worsen in…
Read More
Balovaptan, a novel drug that binds to and blocks vasopressin 1A (V1a) receptors, does not improve social communication in children and adolescents with autism spectrum disorder (ASD), new research shows. Efficacy analysis from a…
Read More
